Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

Inclusion Criteria: * Male or female patients ≥ 18 and ≤ 75 years of age at the time of signing the informed consent form (ICF)； * History of gout according to the 2015 American College Rheumatology/European League Against Rheumatism (ACR/EULAR) Gout Classification Criteria，with serum urate (sUA) levels ≥480μmol/L； * Body mass index (BMI) must be within the range of ≥ 18 to ≤ 35 kg/m2； * Participants with childbearing potential must agree to use medically accepted effective contraception during the study period and for 3 months after the last dose * Willing to participate in the study and sign the informed consent form. Exclusion Criteria: * Known or suspected allergy to the study drug or its components, or previous intolerance or contraindications to febuxostat； * HbA1c ≥8% within 2 weeks prior to randomization； * Any of the following laboratory test results within 2 weeks prior to randomization：WBC\<3.0×109/L，Hb\<90g/L，PLT\<80×109/L，ASTorALT\>1.5×ULN，TBIL\>1.5×ULN，Scr\>1.5×ULN，eGFR\<60mL/min/1.73m2； * Use of any other uric acid-lowering drugs or concomitant medications affecting uric acid levels (including but not limited to losartan, calcium channel blockers, fenofibrate, atorvastatin, α-glucosidase inhibitors, insulin sensitizers, DPP4 inhibitors, SGLT2 inhibitors, metformin) within 2 weeks prior to randomization, except for stable dose usage； * Use of aspirin \>100 mg/day or unstable dosage within 2 weeks prior to randomization； * Use o…